Related Experiment Video
Updated: Aug 11, 2026
08:19
Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
Flutamide-induced regression of angiofibroma
G A Gates1, D H Rice, C F Koopmann
1Department of Otolaryngology, Washington University School of Medicine, St. Louis, MO 63110.
The Laryngoscope
|June 11, 1992
Summary
Flutamide, a testosterone receptor blocker, significantly reduced tumor size in four of five patients with juvenile nasopharyngeal angiofibroma (JNA). This hormonal therapy shows promise as a preoperative adjunct to surgery for JNA.
Area of Science:
- Otolaryngology
- Endocrinology
- Oncology
Background:
- Juvenile nasopharyngeal angiofibroma (JNA) is a rare, benign tumor.
- JNA is hypothesized to be an endocrine-responsive tumor, particularly to androgens.
Purpose of the Study:
- To investigate the efficacy of flutamide, a testosterone receptor blocker, in reducing JNA tumor size preoperatively.
- To assess the feasibility and safety of hormonal pharmacoreduction as an adjunct to surgical treatment for JNA.
Main Methods:
- A pilot study involving five young male patients diagnosed with JNA.
- Patients received flutamide treatment for 6 weeks prior to surgical resection.
- Tumor size was assessed using axial computed tomography before and after flutamide therapy.
Main Results:
- Four out of five patients experienced an average tumor shrinkage of 44% after flutamide treatment.
- Flutamide was well-tolerated by the patients.
- Serum testosterone levels remained normal 2 or more years post-treatment.
Conclusions:
- Preoperative hormonal pharmacoreduction using flutamide is a feasible adjunctive therapy for JNA.
- This approach may lead to reduced blood loss during surgical intervention.
- Further clinical trials are warranted to validate this treatment strategy before widespread adoption.
